Effect of subcutaneous recombinant human erythropoetin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase 11 trial
1998

Effect of Erythropoietin on Cancer Patients Receiving Radiotherapy

Sample size: 48 publication Evidence: moderate

Author Information

Author(s): PJ Sweeney, D Nicolae, L Ignacio, L Chen, M Roach III, W Wara, KC Marcus, S Vijayakumar

Primary Institution: University of Chicago

Hypothesis

Does recombinant human erythropoietin improve safety, efficacy, and quality of life for cancer patients undergoing radiotherapy?

Conclusion

Recombinant human erythropoietin significantly improved hemoglobin levels in cancer patients undergoing radiotherapy compared to controls.

Supporting Evidence

  • Patients receiving r-HuEPO had a mean hemoglobin increase of 0.41 g/dl per week.
  • 41.6% of r-HuEPO-treated patients achieved target hemoglobin levels compared to none in the control group.
  • The mean platelet count decline was less in r-HuEPO-treated patients compared to controls.
  • Quality of life scores were higher in the r-HuEPO group, although not statistically significant.

Takeaway

This study shows that a medicine called erythropoietin can help cancer patients who are getting radiation therapy by making their blood healthier.

Methodology

A randomized, open-label trial comparing r-HuEPO treatment with a control group in cancer patients undergoing radiotherapy.

Limitations

The study did not establish the optimum dose and scheduling of r-HuEPO for cancer patients.

Participant Demographics

48 patients, half men and half women, with various types of cancer including lung, breast, prostate, and cervical.

Statistical Information

P-Value

0.0012

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication